CNDP1 Overexpression by Promoter Hypomethylation Predicts Poor Prognosis and Immunotherapy Response in Mucosal Melanoma
Cancer Science · 2025
DOI: 10.1111/cas.70062 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2025. Verfasst von Jia Jia und 13 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Molecular Oncology, Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospi…. Hauptthemen laut MEDLINE: DNA Methylation, Promoter Regions, Genetic, Melanoma, Dipeptidases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Beijing Municipality, Beijing Municipal Administration of Hospitals' Ascent Plan, National Natural Science Foundation of China.
Abstract (Originalsprache)
Mucosal melanoma (MM) is an uncommon and aggressive malignant tumor, characterized by a scarcity of effective treatment options and novel biomarkers. To develop novel biomarkers, a total of 89 MM tumor samples (including 50 cases in the discovery cohort and 39 cases in the validation cohort) were collected from three medical centers. Targeted bisulfite sequencing and RNA sequencing were conducted in the discovery cohort, and Cox regression analysis was employed to evaluate DNA methylation (methyDNA) and RNA expression data. Our results revealed that, compared to control samples, MM tumor samples exhibited a hypomethylated status of the Carnosine dipeptidase 1 ( CNDP1 ) promoter ( p < 0.001), which significantly up‐regulated its gene expression ( R = −0.815, p < 0.001) and indicated a worse prognosis ( p = 0.002, hazard ratio (HR) (95% confidence interval, CI) = 0.01 (6.78E‐04 ~ 0.20)). Using immunohistochemical staining, we found that CNDP1 protein was expressed in 81.8% of MM cases (36/44, including 1+/2+/3+), and high expression (2+/3+) was associated with significantly decreased overall survival ( p = 0.0120, HR (95% CI) = 2.693 (1.223–5.931)). This pattern is consistent across both discovery and validation cohorts. Moreover, among the 21 patients who received immunotherapy, those with hypomethylated CNDP1 were associated with a ‘cold’ tumor immune microenvironment and suboptimal therapeutic outcomes (Objective Response Rate: 38% vs. 60%; Disease Control Rate: 75% vs. 100%). In conclusion, the overexpression of CNDP1 , driven by promoter hypomethylation, may serve as a potential predictor of poor prognosis and diminished response to immunotherapy in MM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Molecular Oncology, Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical Coll…
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, People's Republic of China.
- Geneseeq Research Institute, Nanjing Geneseeq Technology Inc, Nanjing, People's Republic of China.
- Department of Pathology, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, People's Repu…
ORCID-Profile: Lu Si
Förderung
- Natural Science Foundation of Beijing Municipality
- Beijing Municipal Administration of Hospitals' Ascent Plan
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Jia, J., Gu, J., Gao, L., Liu, K., Dai, J., Zhang, F., Yuan, P., Mao, L., Wei, X., Shao, Y., Guo, J., Xi, Y., Ying, J., & Si, L. (2025). CNDP1 Overexpression by Promoter Hypomethylation Predicts Poor Prognosis and Immunotherapy Response in Mucosal Melanoma. Cancer Science. https://doi.org/10.1111/cas.70062
Vancouver
Jia J, Gu J, Gao L, Liu K, Dai J, Zhang F, et al. CNDP1 Overexpression by Promoter Hypomethylation Predicts Poor Prognosis and Immunotherapy Response in Mucosal Melanoma. Cancer Science. 2025. doi:10.1111/cas.70062
BibTeX
@article{Jia2025,
author = {Jia, Jia and Gu, Junjie and Gao, Lina and Liu, Kaihua and Dai, Jie and Zhang, Fanshuang and Yuan, Pei and Mao, Lili and Wei, Xiaoting and Shao, Yang and Guo, Jun and Xi, Yanfeng and Ying, Jianming and Si, Lu},
title = {CNDP1 Overexpression by Promoter Hypomethylation Predicts Poor Prognosis and Immunotherapy Response in Mucosal Melanoma},
journal = {Cancer Science},
year = {2025},
doi = {10.1111/cas.70062}
}
EUVIMED